Skip to main content
Top
Published in: Trials 1/2019

Open Access 01-12-2019 | Ebola Virus | Commentary

Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context

Authors: Edouard Lhomme, Camara Modet, Augustin Augier, Sylvain Faye, Tienhan Sandrine Dabakuyo-Yonli, Claire Levy-Marchal, Eric D’Ortenzio, Yazdan Yazdanpanah, Geneviève Chêne, Abdoul Habib Beavogui, Laura Richert, the PREVAC study team

Published in: Trials | Issue 1/2019

Login to get access

Abstract

Background

Enrolling participants in clinical trials can be challenging, especially with respect to prophylactic vaccine trials. The vaccination of study personnel in Ebola vaccine trials during the 2014–2016 epidemic played a crucial role in inspiring trust and facilitating volunteer enrollment. We evaluated the ethical and methodological considerations as they applied to an ongoing phase 2 randomized prophylactic Ebola vaccine trial that enrolled healthy volunteers in Guinea, Liberia, Sierra Leone, and Mali in a non-epidemic context.

Methods

On the assumption that the personnel on site involved in executing the protocol, as well as community mobilizers (not involved in the on-site procedures), might also volunteer to enter the trial, we considered both ethical and methodological considerations to set clear rules that can be shared a priori with these persons. We reviewed the scientific and gray literature to identify relevant references and then conducted an analysis of the ethical and methodological considerations.

Results

There are currently no regulations preventing a clinical investigator or site staff from participating in a trial. However, the enrollment of personnel raises the risk of undue influence and challenges the basic ethical principle of voluntary participation. The confidentiality of personal medical information, such as HIV test results, may also be difficult to ensure among personnel. There is a risk of disruption of trial operations due to the potential absence of the personnel for their commitment as trial participants, and there is also a potential for introducing differential behavior of on-site staff as they obtain access to accumulating information during the trial (e.g., the incidence of adverse events). Blinding could be jeopardized, given knowledge of product-specific adverse event profiles and the proximity to unblinded site staff. These aspects were considered more relevant for on-site staff than for community mobilizers, who have limited contact with site staff.

Conclusion

In a non-epidemic context, ethical and methodological considerations limit the collective benefit of enrolling site staff in a vaccine trial. These considerations do not apply to community mobilizers, whose potential enrollment should be considered as long as they meet the inclusion criteria and they are not exposed to any form of coercion.
Literature
2.
go back to reference Osterholm M, Moore K, Ostrowsky J, Kimball-Baker K, Farrar J, Wellcome Trust-CIDRAP Ebola Vaccine Team B. The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats. Lancet Infect Dis. 2016;16(1):e1–9.CrossRef Osterholm M, Moore K, Ostrowsky J, Kimball-Baker K, Farrar J, Wellcome Trust-CIDRAP Ebola Vaccine Team B. The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats. Lancet Infect Dis. 2016;16(1):e1–9.CrossRef
3.
go back to reference Lévy Y, Lane C, Piot P, Beavogui AH, Kieh M, Leigh B, et al. Prevention of Ebola virus disease through vaccination: where we are in 2018. Lancet. 2018;392(10149):787–90.CrossRef Lévy Y, Lane C, Piot P, Beavogui AH, Kieh M, Leigh B, et al. Prevention of Ebola virus disease through vaccination: where we are in 2018. Lancet. 2018;392(10149):787–90.CrossRef
4.
go back to reference Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M, Ballou R. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med. 2017;377(15):1438–47.CrossRef Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M, Ballou R. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med. 2017;377(15):1438–47.CrossRef
5.
go back to reference Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389(10068):505–18.CrossRef Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389(10068):505–18.CrossRef
6.
go back to reference Doe-Anderson J, Baseler B, Driscoll P, Johnson M, Lysander J, McNay L, et al. Beating the odds: successful establishment of a phase II/III clinical research trial in resource-poor Liberia during the largest-ever Ebola outbreak. Contemp Clin Trials Commun. 2016;4:68–73.CrossRef Doe-Anderson J, Baseler B, Driscoll P, Johnson M, Lysander J, McNay L, et al. Beating the odds: successful establishment of a phase II/III clinical research trial in resource-poor Liberia during the largest-ever Ebola outbreak. Contemp Clin Trials Commun. 2016;4:68–73.CrossRef
7.
go back to reference Mooney T, Smout E, Leigh B, Greenwood B, Enria L, Ishola D. EBOVAC-Salone: lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country. Clin Trials. 2018;15(5):436–43.CrossRef Mooney T, Smout E, Leigh B, Greenwood B, Enria L, Ishola D. EBOVAC-Salone: lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country. Clin Trials. 2018;15(5):436–43.CrossRef
9.
go back to reference Enria L, Lees S, Smout E, Mooney T, Tengbeh AF, Leigh B, et al. Power, fairness and trust: understanding and engaging with vaccine trial participants and communities in the setting up the EBOVAC-Salone vaccine trial in Sierra Leone. BMC Public Health. 2016;16(1):1140.CrossRef Enria L, Lees S, Smout E, Mooney T, Tengbeh AF, Leigh B, et al. Power, fairness and trust: understanding and engaging with vaccine trial participants and communities in the setting up the EBOVAC-Salone vaccine trial in Sierra Leone. BMC Public Health. 2016;16(1):1140.CrossRef
10.
go back to reference Laverack G, Manoncourt E. Key experiences of community engagement and social mobilization in the Ebola response. Glob Health Promot. 2016;23(1):79–82.CrossRef Laverack G, Manoncourt E. Key experiences of community engagement and social mobilization in the Ebola response. Glob Health Promot. 2016;23(1):79–82.CrossRef
11.
go back to reference Conn VS, Valentine JC, Cooper HM, Rantz MJ. Grey literature in meta-analyses. Nurs Res. 2003;52(4):256–61.CrossRef Conn VS, Valentine JC, Cooper HM, Rantz MJ. Grey literature in meta-analyses. Nurs Res. 2003;52(4):256–61.CrossRef
12.
go back to reference World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.CrossRef World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.CrossRef
13.
go back to reference National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont report: Ethical principles and guidelines for the protection of human subjects of research. Bethesda: The Commission; 1978. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont report: Ethical principles and guidelines for the protection of human subjects of research. Bethesda: The Commission; 1978.
14.
go back to reference Council for International Organizations of Medical Sciences (CIOMS). International Ethical Guidelines for Health-related Research Involving Humans, fourth edition. Geneva: CIOMS; 2016. Council for International Organizations of Medical Sciences (CIOMS). International Ethical Guidelines for Health-related Research Involving Humans, fourth edition. Geneva: CIOMS; 2016.
16.
go back to reference Resnik D. Employees as research participants: ethical and policy issues. IRB: Ethics Hum Res. 2016;38(4):11–6. Resnik D. Employees as research participants: ethical and policy issues. IRB: Ethics Hum Res. 2016;38(4):11–6.
Metadata
Title
Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context
Authors
Edouard Lhomme
Camara Modet
Augustin Augier
Sylvain Faye
Tienhan Sandrine Dabakuyo-Yonli
Claire Levy-Marchal
Eric D’Ortenzio
Yazdan Yazdanpanah
Geneviève Chêne
Abdoul Habib Beavogui
Laura Richert
the PREVAC study team
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Ebola Virus
Published in
Trials / Issue 1/2019
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-019-3487-0

Other articles of this Issue 1/2019

Trials 1/2019 Go to the issue